Literature DB >> 32927246

Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder.

Gianluigi Tanda1, Melinda Hersey2, Briana Hempel2, Zheng-Xiong Xi2, Amy Hauck Newman2.   

Abstract

Pharmacotherapeutics for treatment of psychostimulant use disorder are still an unmet medical goal. Recently, off label use of modafinil (MOD), an approved medication for treatment of sleep disturbances, has been tested as a therapeutic for cocaine and methamphetamine use disorder. Positive results have been found in subjects dependent on psychostimulants without concurrent abuse of other substances. Novel structural analogs of MOD have been synthesized in the search for compounds with potentially broader therapeutic efficacy than the parent drug. In the present report we review their potential efficacy as treatments for psychostimulant abuse and dependence assessed in preclinical tests. Results from these preclinical proof of concept studies reveal that some modafinil analogs do not possess typical cocaine-like neurochemical and behavioral effects. Further, they might blunt the reinforcing effects of psychostimulants in animal models, suggesting their potential efficacy as pharmacotherapeutics for treatment of psychostimulant use disorders. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32927246      PMCID: PMC8247144          DOI: 10.1016/j.coph.2020.07.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  65 in total

1.  R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.

Authors:  Claus J Loland; Maddalena Mereu; Oluyomi M Okunola; Jianjing Cao; Thomas E Prisinzano; Sonia Mazier; Theresa Kopajtic; Lei Shi; Jonathan L Katz; Gianluigi Tanda; Amy Hauck Newman
Journal:  Biol Psychiatry       Date:  2012-04-25       Impact factor: 13.382

2.  Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.

Authors:  Vitor S Tardelli; Adam Bisaga; Felipe B Arcadepani; Gilberto Gerra; Frances R Levin; Thiago M Fidalgo
Journal:  Psychopharmacology (Berl)       Date:  2020-06-29       Impact factor: 4.530

3.  Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers.

Authors:  James J Mahoney; Brian J Jackson; Ari D Kalechstein; Richard De La Garza; Lee C Chang; Thomas F Newton
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-04       Impact factor: 5.176

4.  Heterocyclic Analogues of Modafinil as Novel, Atypical Dopamine Transporter Inhibitors.

Authors:  Predrag Kalaba; Nilima Y Aher; Marija Ilić; Vladimir Dragačević; Marcus Wieder; Andras G Miklosi; Martin Zehl; Judith Wackerlig; Alexander Roller; Tetyana Beryozkina; Bojana Radoman; Sivaprakasam R Saroja; Wolfgang Lindner; Eduardo Perez Gonzalez; Vasiliy Bakulev; Johann Jakob Leban; Harald H Sitte; Ernst Urban; Thierry Langer; Gert Lubec
Journal:  J Med Chem       Date:  2017-11-09       Impact factor: 7.446

5.  Oral modafinil facilitates intracranial self-stimulation in rats: comparison with methylphenidate.

Authors:  Matthew F Lazenka; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2017-06       Impact factor: 2.293

6.  Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats.

Authors:  Brendan J Tunstall; Chelsea P Ho; Jianjing Cao; Janaína C M Vendruscolo; Brooke E Schmeichel; Rachel D Slack; Gianluigi Tanda; Alexandra J Gadiano; Rana Rais; Barbara S Slusher; George F Koob; Amy H Newman; Leandro F Vendruscolo
Journal:  Neuropharmacology       Date:  2017-12-05       Impact factor: 5.250

7.  A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.

Authors:  Kyle M Kampman; Kevin G Lynch; Helen M Pettinati; Kelly Spratt; Michael R Wierzbicki; Charles Dackis; Charles P O'Brien
Journal:  Drug Alcohol Depend       Date:  2015-08-14       Impact factor: 4.492

Review 8.  Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.

Authors:  Paul W Czoty; William W Stoops; Craig R Rush
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

9.  Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability.

Authors:  Rachel D Slack; Therese C Ku; Jianjing Cao; JoLynn B Giancola; Alessandro Bonifazi; Claus J Loland; Alexandra Gadiano; Jenny Lam; Rana Rais; Barbara S Slusher; Mark Coggiano; Gianluigi Tanda; Amy Hauck Newman
Journal:  J Med Chem       Date:  2019-11-14       Impact factor: 7.446

10.  The dopamine hypothesis of drug addiction and its potential therapeutic value.

Authors:  Marco Diana
Journal:  Front Psychiatry       Date:  2011-11-29       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.